Truist Financial Corp, a financial services company, has recently reduced its stake in Horizon Therapeutics Public Limited Company by 89.4%. According to their most recent disclosure with the Securities & Exchange Commission, Truist Financial Corp now owns 7,239 shares of Horizon Therapeutics Public’s stock after selling 61,321 shares during the first quarter. At the end of this reporting period, these holdings were valued at $790,000.
Horizon Therapeutics Public Limited Company is a prominent biotechnology company that specializes in the development and commercialization of medicines for individuals impacted by rare, autoimmune, and severe inflammatory diseases. The company’s main focus lies in discovering innovative treatment options to address critical medical needs.
With an extensive portfolio of 12 medicines covering various therapeutic areas such as rare diseases, gout, ophthalmology, and inflammation, Horizon Therapeutics Public aims to provide effective solutions for patients facing challenging health conditions.
The decision made by Truist Financial Corp to reduce its stake in Horizon Therapeutics Public reflects a shift in their investment strategy. It is important to note that such actions are not uncommon among financial institutions as they continuously reassess their investment portfolios based on various factors.
As of August 23rd, 2023; it remains crucial for investors and stakeholders to closely monitor any developments regarding both Truist Financial Corp and Horizon Therapeutics Public Limited Company. This will help them stay informed about potential impacts on the companies’ respective financial positions and market standings.
Overall, this change in ownership signifies an evolution within the investment landscape among these two entities. Being up-to-date with crucial updates and reports is paramount for those interested in tracking the progress of Horizon Therapeutics Public Limited Company or maintaining knowledge about trends within the biopharmaceutical industry.
Institutional Investors Show Confidence in Horizon Therapeutics Public as Company Sees Ownership Changes
Horizon Therapeutics Public Limited, a biopharmaceutical company listed on NASDAQ under the ticker symbol HZNP, has recently seen some significant changes in its ownership structure. Several institutional investors and hedge funds have made substantial investments in the company, demonstrating their confidence in its potential for growth and success.
One notable investor is T. Rowe Price Investment Management Inc., which purchased a new stake in Horizon Therapeutics Public during the fourth quarter of the previous year. The investment was valued at an impressive $460,920,000, highlighting T. Rowe Price’s belief in the company’s prospects.
Soros Fund Management LLC also joined the group of investors purchasing shares of Horizon Therapeutics Public during the fourth quarter, with a stake worth $325,297,000. This further demonstrates strong investor interest in the company and its future performance.
Norges Bank, the central bank of Norway, also decided to invest in Horizon Therapeutics Public during the same period. Its stake amounted to $249,778,000, indicating that even international financial institutions recognize the potential of this biopharmaceutical firm.
Avoro Capital Advisors LLC took its position in Horizon Therapeutics Public one step further by increasing its ownership by 36.6% during the fourth quarter. As a result, Avoro Capital Advisors now owns an impressive 7 million shares of the company’s stock—valued at approximately $796,600,000 after purchasing an additional 1.875 million shares.
Finally, PSquared Asset Management AG completed this group of institutional investors and hedge funds by buying a new stake worth $181,730,000 in Horizon Therapeutics Public during the same period.
Institutional investors and hedge funds now own approximately 80.66% of Horizon Therapeutics Public’s stock. This level of ownership by established financial players suggests that confidence in the company’s potential is widespread within these circles.
Several brokerages have also commented on the stock, offering their assessments of Horizon Therapeutics Public. TheStreet downgraded the company’s rating from “b-” to “c+” in a research report released on May 8th earlier this year.
In contrast, StockNews.com began its coverage of Horizon Therapeutics Public on August 17th with a “buy” rating on the stock, indicating that they believe in the company’s growth prospects.
Overall, there are seven analysts who have given the stock a hold rating while one analyst has assigned a buy rating to Horizon Therapeutics Public. According to Bloomberg, the average consensus target price for the company is $110.71.
Moving away from ownership and analyst ratings, let us evaluate some key financial indicators to further analyze Horizon Therapeutics Public. Currently trading at $105.27 per share, the company boasts a current ratio of 4.27 and quick ratio of 4.09—a testament to its strong liquidity position.
Horizon Therapeutics Public also maintains a debt-to-equity ratio of 0.48—an attractive figure compared to industry peers—which indicates prudent financial management and reduced risk.
The firm’s fifty-day moving average stands at $102.40 while its two-hundred-day moving average is recorded at $105.82—indicating relative stability in its stock price over these time periods.
Consistently hitting new highs throughout this past year, Horizon Therapeutics Public reached its peak at $113.83 but has since experienced some fluctuations in price.
The biopharmaceutical company currently holds a market capitalization of $24.11 billion and operates with a price-to-earnings (P/E) ratio of 56.29—suggesting that investors perceive significant growth potential in its operations and future earnings.
Speaking of earnings, Horizon Therapeutics Public reported strong results for its most recent quarter ending on August 8th this year. The company surpassed analyst expectations by posting earnings per share of $1.20, beating estimates by $0.08.
Furthermore, its quarterly revenue reached $945.00 million—exceeding analyst projections of $873.52 million—reflecting a 7.8% increase from the previous year during the same period.
The company’s net margin was recorded at an impressive 12.02%, showcasing its ability to effectively convert revenue into profit. Additionally, Horizon Therapeutics Public achieved a return on equity of 20.46%, suggesting that management is efficiently utilizing shareholder investments to generate returns.
Based on these results and strong financial indicators, research analysts anticipate that Horizon Therapeutics Public Limited will post an EPS (earnings per share) of 4.7 for the current fiscal year.
In summary, Horizon Therapeutics Public has attracted significant investment interest from institutional investors and hedge funds alike, solidifying its position as a promising player in the biopharmaceutical industry.
With positive earnings reports and robust financial indicators, coupled with supportive analyst ratings and target prices, it seems that Horizon Therapeutics Public has set a solid foundation for continued growth in the coming months and beyond.
Source: beststocks.com
